Pacira BioSciences stock weighs Q2 growth and lower guidance
Published on 10/04/2026 at 12:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pacira BioSciences stock closed at USD 25.21 on Nasdaq on October 2, 2026, after the company reported second-quarter revenue growth and reduced its full-year sales outlook. The latest figures put the focus on whether stronger commercial execution can offset a smaller product portfolio.
Q2 revenue beats expectations
According to Zacks in its September 2026 review, Pacira posted Q2 2026 revenue of USD 192.4 million, up 6.2 percent from the year-earlier quarter and above the USD 190.0 million consensus estimate. Adjusted earnings reached USD 0.73 per share, beating the USD 0.64 consensus estimate, while Exparel net product sales increased 3 percent to USD 147.8 million.
The comparison is positive, but the guidance change is the more important portfolio signal. Following the July 31, 2026, sale of iovera to Zimmer Biomet, Pacira lowered full-year 2026 revenue guidance from USD 745-770 million to USD 735-760 million, while maintaining its Exparel sales outlook at USD 600-620 million, according to Zacks.
Analysts set targets above the quote
Oppenheimer initiated coverage on September 23, 2026, with an Outperform rating and a USD 32.00 price target, as reported by MarketBeat. Its target stands 27.0 percent above the October 2 reference price, calculated from USD 32.00 and USD 25.21.
MarketScreener listed nine analysts and a consensus rating of Outperform with an average target of USD 30.00 on September 23, 2026. That average lies 19.0 percent above the USD 25.21 reference price, while Yahoo Finance showed a target range of USD 23.00 to USD 38.00.
Stock stays below its yearly high
PCRX closed 9.0 percent below its USD 27.66 52-week high and 34.1 percent above its USD 18.80 low on October 2, 2026. Volume was 469,793 shares, and market capitalization stood at USD 991.6 million, giving investors a compact valuation backdrop for the revenue and guidance trade-off.
Pacira BioSciences stock key facts
- Company: Pacira BioSciences, Inc.
- ISIN: US6951271005
- Ticker: PCRX
- Trading venue: Nasdaq
- Price (as of October 2, 2026, 4:00 p.m. ET): USD 25.21 Closing price (October 2, 2026)
- Market capitalization: USD 991.6 million (as of October 2, 2026)
- 52-week range: USD 18.80-27.66 (as of October 2, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
